New nanotherapy could potential treat Crohn’s disease in children
A novel nanotherapy can decrease intestinal inflammation and shrink lesions in rodent models of Crohn's disease, a study has shown.
List view / Grid view
A novel nanotherapy can decrease intestinal inflammation and shrink lesions in rodent models of Crohn's disease, a study has shown.
The drug combination of difluoromethylornithine and AMXT 1501 has shown success against Diffuse Intrinsic Pontine Glioma in animal models.
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
Through a series of experiments, researchers have identified small drug molecules that can inhibit filoviruses such as Ebola and Marburg.
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
A team has developed enterocyte-like cells from hiPSCs, which can be used to study the absorption of novel oral drugs.
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.